Navigation Links
Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
Date:11/7/2011

cell and antibody responses were observed in its proof-of-principle Phase I clinical study of Inovio's preventive H5N1 (avian) influenza SynCon® DNA vaccine, VGX-3400X. The vaccine, delivered using Inovio's proprietary electroporation system, was generally safe and well tolerated at all dose levels, with no vaccine-related serious adverse events. Additional data are expected in 4Q 2011.

Inovio launched a second Phase I clinical study as part of its universal influenza vaccine, INO-3510, a SynCon® vaccine for H1N1 and H5N1 influenza, using its skin-targeted ID delivery device. Preliminary safety and immune response data are expected in the first quarter of 2012.

Strong immune responses and safety were demonstrated from the first (US) cohort of healthy subjects in a Phase I study assessing Inovio's PENNVAX™-G global HIV vaccine plus a virus vector vaccine, Modified Vaccinia Ankara-Chiang Mai Double Recombinant (MVA-CMDR), as a unique prime-boost preventive HIV vaccination strategy. Enrollment is continuing at three sites in Africa in the next phase of the study.

Best-in-class immune responses were observed in the final data from a Phase I clinical study of Inovio's PENNVAX™-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe. The investigators in this study concluded that PENNVAX™-B + IL-12 plasmid delivered via electroporation led to frequencies and magnitudes of cellular immune responses equal to or greater than those reported from current vector-based HIV vaccines such as adenovirus or traditional DNA vaccination without electroporation.

Enrollment is ongoing in the Phase II clinical studies being run by Inovio's collaborators ChronTech and the University of Southampton for their DNA vaccines for hepatitis C virus and acute and chronic myeloid leukemia, with interim data expected in 2012.

Inovio previously announced a research collabor
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
(Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
(Date:2/27/2015)... Mass. and JERUSALEM , ... biopharma company developing octreotide capsules, its lead product for ... a $70 million Series E financing round. Participants in ... Sofinnova Ventures, and an undisclosed blue chip public investment ... Capital, 7 Med Health Ventures, Abingworth and ARCH Venture ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... 2011 - Vention Medical, a leading full-service ... acquisition of ANSAmed, Ireland,s premier  provider of ... and multi-lumen extrusion capabilities, and catheter design, ... acquisition of ANSAmed will expand Vention Medical,s ...
... 26, 2011 Varian Medical Systems (NYSE: VAR ... with Bank of America, N.A. to repurchase $250 million of ... the company amended its revolving credit facility with Bank of ... to $300 million. Under the accelerated repurchase agreement, ...
Cached Medicine Technology:Vention Medical Acquires ANSAmed 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:2/28/2015)... Santa Cruz, california (PRWEB) February 28, 2015 ... an ever growing number of practicing physicians as a way ... experience, training or education regarding Cannabis as medicine. Since the ... have been very few resources available to licensed physicians ... treatment to a patient. Dr. Deborah Malka in Santa ...
(Date:2/28/2015)... Calgary, AB (PRWEB) February 28, 2015 ... and is now a distributor of the machine. The ... part of their license, like a franchise model. The ... people prevent and reverse heart disease. To buy ... Heart Fit Clinic can help individuals through this process ...
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, ... pleased to announce the development of Q-Suite 5.9. Building ... of Q-Suite, this new version will include enhancements to ... features to the leading edge call center software. General ... add features to enhance security and protection. Administrators will ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... Company) (NYSE: BDX ), a global medical technology company,announced today that ... 2008 Annual Credit Suisse Healthcare Conference ... pm ET, Lazard Capital Markets 5th Annual ... 10:55 a.m. ET, A live webcast of BD,s ...
... (human papillomavirus) vaccines and the validation of a simple oral ... studies by a Johns Hopkins Kimmel Cancer Center investigator. , ... identify HPV infection as the cause of certain oral cancers ... risk factor for these cancers, reports her latest work in ...
... Taking Medications for Blood Pressure, Cholesterol, ... Asthma, ADD/ADHD, Depression and Diabetes, ST. LOUIS, Nov. 3 ... type 2 diabetes medications between 2002 and,2005, with girls between ... One likely cause: Obesity, which is closely associated with type,2 ...
... Declared, ACTON, Mass., Nov. 3 Psychemedics Corporation,(Nasdaq: ... for the,period ended September 30, 2008. The Company also ... shareholders of record as of,December 3, 2008 to be ... 49th consecutive quarterly dividend., The Company,s third quarter ...
... Robbins & Myers, Inc.,(NYSE: RBN ) announced ... Conference on November 11, 2008. The Company will be ... and Christopher,M. Hix, Vice President and Chief Financial Officer., ... CST, at,the Four Seasons Hotel in Chicago, Illinois. It ...
... Leading Cause of Death in U.S., SWANTON, Vt., ... Month, to help raise awareness about Chronic,Obstructive Pulmonary Disease ... will be making downloadable,tips available to COPD patients on ... November newsletter and blogs to raising awareness,about this 4th ...
Cached Medicine News:Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 2Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 3Health News:Tweens and Teens Double Use of Diabetes Drugs 2Health News:Tweens and Teens Double Use of Diabetes Drugs 3Health News:Tweens and Teens Double Use of Diabetes Drugs 4Health News:Psychemedics Corporation Announces Third Quarter Results 2Health News:Psychemedics Corporation Announces Third Quarter Results 3Health News:Psychemedics Corporation Announces Third Quarter Results 4Health News:Psychemedics Corporation Announces Third Quarter Results 5Health News:AllerAir Dedicates November to COPD Awareness Month 2
... height permits optimal leg position for the seated ... cast with the foot/ankle at 90 degrees to ... tongue of the stand. Stockinette is pulled over ... is used in a routine fashion. The cast ...
... Techno-Aide provides the highest level ... highest quality lead protective eyewear. ... + tolerance allowed. Mfg supervised by ... All lens meet or exceed standards ...
... designer goggle includes a non-slip ... a more comfortable, even weight ... head strap design is easily ... acrylic side shields provide added ...
... The wrap frame is constructed of ... while minimizing potential breakage. The molded ... a full saddle bridge to distribute weight ... peripheral vision with leaded glass side shields. ...
Medicine Products: